New entity poised to accelerate the development of Aerami's diverse pipeline of next-generation inhaled therapies
AER-901, Aerami's proprietary inhaled, nebulized formulation of imatinib, targeted to advance in 2022 into a Phase 2/3 clinical trial for PAH
Aerami expected to file in 2022 a 510(k) for its proprietary AFINA inhaler platform
PR Newswire
DURHAM, N.C. and NEW YORK, Dec. 7, 2021